Emactuzumab

Emactuzumab (pronunciation: e-mac-tu-zu-mab) is a monoclonal antibody designed for the treatment of various cancer types. It is developed by Roche, a Swiss multinational healthcare company.

Etymology

The name "Emactuzumab" is derived from the International Nonproprietary Names (INN), where "Emactu-" refers to the target, and "-mab" is a common suffix for monoclonal antibodies.

Mechanism of Action

Emactuzumab works by targeting and inhibiting the Colony Stimulating Factor 1 Receptor (CSF1R), a type of protein found on the surface of certain cells that can promote tumor growth and survival. By blocking CSF1R, Emactuzumab can help to slow down or stop the growth of cancer cells.

Clinical Trials

Emactuzumab has been studied in several clinical trials for its effectiveness in treating different types of cancer, including solid tumors and sarcomas. The results of these trials have shown promising potential for the use of Emactuzumab in cancer treatment.

Related Terms

• Monoclonal antibody
• Cancer
• Tumor
• Protein
• Clinical trial
• Solid tumor
• Sarcoma

External links

• Medical encyclopedia article on Emactuzumab
• Wikipedia's article - Emactuzumab

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski